3-氨基-2,2-二甲基丙酸甲酯盐酸盐 | 177269-37-3

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 3-氨基-2,2-二甲基丙酸甲酯盐酸盐
• 中文别名: 2,2-二甲基-3-氨基丙酸甲酯盐酸盐
• 英文名称: methyl 3-amino-2,2-dimethylpropanoate hydrochloride
• 英文别名: methyl 3-amino-2,2-dimethylpropanoate;hydrochloride
• CAS: 177269-37-3
• 化学式: C₆H₁₃NO₂*ClH
• mdl: MFCD10758092
• 分子量: 167.636
• InChiKey: PHPVVUDRVIMHOI-UHFFFAOYSA-N

物化性质

• 熔点：
  167-168°

计算性质

• 辛醇/水分配系数(LogP)：
  0.33
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  52.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2922499990
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  3-氨基-2,2-二甲基丙酸甲酯盐酸盐 在 吗啉 、 4-二甲氨基吡啶 、 四(三苯基膦)钯 、 三甲基氯硅烷 、 potassium carbonate 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 间氯过氧苯甲酸 、 三氟乙酸 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 氯仿 、 水 、 乙腈 为溶剂， 反应 95.5h， 生成 cryptophycin 52
  参考文献：
  名称：

  Cryptophycin-55/52 based antibody-drug conjugates: Synthesis, efficacy, and mode of action studies

  摘要：

  Cryptophycin-52 (CR52), a tubulin inhibitor, exhibits promising antitumor activity in vitro (picomolar level) and in mouse xenograft models. However, the narrow therapeutic window in clinical trials limits its further development. Antibody-drug conjugate (ADC), formed by coupling cytotoxic compound (payload) to an antibody via a linker, can deliver drug to tumor locations in a targeted manner by antibody, enhancing the therapeutic effects and reducing toxic and side effects. In this study, we aim to explore the possibility of CR52-based ADC for tumor targeted therapy. Due to the lack of a coupling site in CR52, its prodrug cryptophycin-55 (CR55) containing a free hydroxyl was synthesized and conjugated to the model antibody trastuzumab (anti-HER2 antibody drug approved by FDA for breast cancer therapy) via the linkers based on Mc-NHS and Mc-Val-Cit-PAB-PNP. The average drug-to-antibody ratios (DARs) of trastuzumab-CR55 conjugates (named T-L1-CR55, T-L2-CR55, and T-L3-CR55) were 3.50, 3.29, and 3.35, respectively. These conjugates exhibited potent cytotoxicity in HER2-positive tumor cell lines with IC50 values at low nanomolar levels (0.58-1.19 nM). Further, they displayed significant antitumor activities at the doses of 10 mg/kg in established ovarian cancer (SKOV3) and gastric cancer (NCI-N87) xenograft models without overt toxicities. Finally, the drug releases were analyzed and the results indicated that T-L3-CR55 was able to effectively release CR55 and further epoxidized to CR52, which may be responsible for its best performance in antitumor activities. In conclusion, our results demonstrated that these conjugates have the potential for tumor targeted therapy, which provides insights to further research the CR55/CR52-based ADC for tumor therapy. (C) 2020 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2020.112364
• 作为产物：
  描述：

  3-(叔丁氧基羰基)-2,2-二甲基丙酸甲酯 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 以100%的产率得到3-氨基-2,2-二甲基丙酸甲酯盐酸盐
  参考文献：
  名称：

  [EN] NOVEL CRYPTOPHYCIN COMPOUNDS AND CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
  [FR] NOUVEAUX COMPOSÉS ET CONJUGUÉS DE CRYPTOPHYCINE, LEUR PRÉPARATION ET LEUR UTILISATION THÉRAPEUTIQUE

  摘要：

  本发明涉及公式（I）的隐藻素化合物。该发明还涉及隐藻素有效载荷、隐藻素偶联物、含有它们的组合物及其治疗用途，尤其是作为抗癌剂。该发明还涉及制备这些偶联物的过程。

  公开号：

  WO2017076998A1

文献信息

• [EN] 4 -HYDROXY- ISOQUINOLINE COMPOUNDS AS HIF HYDROXYLASE INHIBITORS<br/>[FR] COMPOSÉS 4-HYDROXY-ISOQUINOLÉINE COMME INHIBITEURS D'HYDROXYLASE HIF
  申请人：FIBROGEN INC

  公开号：WO2013134660A1

  公开（公告）日：2013-09-12

  The present invention relates to novel compounds of formula (I), and compositions capable of inhibiting PHD1 enzyme activity selectively over other isoforms, for example, PHD2 and/or PHD3 enzymes. The invention also relates to compounds of formula (I) for use in disorders such as muscle degeneration, colitis, IBD, and certain ischemias.

  本发明涉及式(I)的新化合物，以及能够选择性地抑制PHD1酶活性而不影响其他同工酶（例如PHD2和/或PHD3酶）的组合物。该发明还涉及式(I)的化合物在肌肉退化、结肠炎、炎症性肠病和某些缺血症等疾病中的应用。
• [EN] SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME<br/>[FR] COMPOSÉS 1,1'-BIPHÉNYLE SUBSTITUÉS ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ARBUTUS BIOPHARMA INC

  公开号：WO2021158481A1

  公开（公告）日：2021-08-12

  The present invention includes substituted 1,1'-biphenyl compounds, analogues thereof, and compositions comprising the same. In one aspect, the compounds contemplated in the invention can be used to treat, ameliorate, or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient. In another aspect, the compounds contemplated in the invention can be used to treat, ameliorate, and/or prevent cancer in a patient.

  本发明包括取代的1,1'-联苯化合物，其类似物，以及包含它们的组合物。在一个方面，本发明中考虑的化合物可用于治疗、改善或预防患者体内的乙型肝炎病毒（HBV）和/或丙型肝炎病毒（HDV）感染。在另一个方面，本发明中考虑的化合物可用于治疗、改善和/或预防患者体内的癌症。
• Quinazolinone Compound and Application Thereof
  申请人：LUOXIN PHARMACEUTICAL (SHANGHAI) CO., LTD.

  公开号：US20200317660A1

  公开（公告）日：2020-10-08

  The present invention relates to a series of quinazolinone compounds and applications thereof as PI3Kα inhibitors. In particular, the present invention relates to a compound shown in formula (I) and a tautomer or pharmaceutically acceptable salt thereof.

  本发明涉及一系列喹唑啉酮化合物及其作为PI3Kα抑制剂的应用。具体而言，本发明涉及一种在式（I）中显示的化合物及其互变异构体或药用可接受的盐。
• Design, synthesis and biological evaluation of theophylline containing variant acetylene derivatives as α-amylase inhibitors
  作者：Radhakrishnam Raju Ruddarraju、Gangarapu Kiran、Adharvana Chari Murugulla、Ravichandar Maroju、Devarakonda Krishna Prasad、Boyina Hemanth Kumar、Vasudha Bakshi、Nukala Shravya Reddy

  DOI：10.1016/j.bioorg.2019.103120

  日期：2019.11

  pharmacophore with theophylline and acetylene moieties was constructed by using a fragment-based drug design and a series of twenty theophylline containing acetylene conjugates were designed and synthesized, and all the compounds were evaluated by enzyme-based in vitro α-amylase inhibition activity. The in vitro evaluation revealed that most of the compounds displayed good inhibitory activities, and among

  利用基于片段的药物设计方法构建了具有茶碱和乙炔部分的新型药效团，设计并合成了二十多种含茶碱的乙炔共轭物，并通过基于酶的体外α-淀粉酶抑制活性对所有化合物进行了评价。在体外评价表明大多数化合物表现出良好的抑制活性，以及它们之间9个类似物13-15，20，21和24-27分别显示出更多或几乎与IC等效抑制活性50与标准阿卡波糖1.37±0.26μM相比，值分别为1.11±0.07、1.14±0.17、1.07±0.01和1.21±0.03、1.33±0.09、1.17±0.01、1.05±0.02、1.61±0.04、1.02±0.03μM。此外，进行分子对接模拟研究以鉴定合成的类似物在α-淀粉酶（PBD ID：4GQR）的结合位点的相互作用和结合模式。在合成的类似物中，基于α-淀粉酶抑制活性选择了两种化合物25和27，并通过高脂饮食-链脲佐菌素（HFD-STZ）模型对正常大鼠的体内抗糖尿病活性进行了评估。剂量为10
• TETRAHYDROCARBOLINE DERIVATIVE
  申请人：Ohata Akira

  公开号：US20130109699A1

  公开（公告）日：2013-05-02

  An object of the present invention is to provide a drug having the inhibitory activity on ENPP2 which is a different target from that of the existing drug, as a medicament useful in a urinary excretion disorder patient for whom the existing drug has the insufficient effect. The present invention provides a compound represented by the general formula (I): (wherein definition of each group is as defined in the description) having the ENPP2 inhibitory activity, a salt thereof or a solvate thereof or a prodrug thereof, and an agent for preventing or treating urinary excretion disorder and/or improving symptoms thereof, containing them as an active ingredient.

  本发明的目的是提供一种药物，具有对ENPP2具有抑制活性，该活性与现有药物的靶点不同，作为一种对现有药物效果不足的尿液排泄障碍患者有用的药物。本发明提供了一种由通式（I）表示的化合物：（其中每个基团的定义如描述中所定义）具有ENPP2抑制活性，其盐或溶剂或前药，以及作为活性成分的含有它们的用于预防或治疗尿液排泄障碍和/或改善症状的药剂。